As the pandemic's death toll approached one million in late 2020, medicine was still searching for reliable signals amid the uncertainty of who would survive hospitalization. A Harvard research team found one such signal in an overlooked corner of routine blood work: the variation in size among a patient's red blood cells. Their study of 1,641 patients across Boston hospitals revealed that this ordinary measurement — red blood cell distribution width, or RDW — carried an extraordinary predictive weight, pointing toward mortality risk long before clinical deterioration became visible to the eye
High Red Blood Cell Width Predicts Severe COVID-19 Risk, Harvard Study Finds
Study conducted during early COVID-19 pandemic when global deaths were approaching one million, with elevated mortality rates among elderly and immunocompromised populations.
A simple blood test could flag which patients needed closer watching
Mark
Why does the size variation of red blood cells matter in COVID? That seems almost too simple.
Mimi
It does seem simple, but RDW is really a window into how stressed the body is. When you're fighting a severe infection, your bone marrow starts producing red blood cells faster and less uniformly. The variation itself is a sign of chaos in the system.
Mark
So it's not that the cells themselves are dangerous—it's what they signal?
Mimi
Exactly. RDW is a symptom of what's happening underneath. In COVID, we know the virus triggers a cytokine storm, abnormal clotting, organ failure. RDW seems to track alongside all of that. It's like watching the body's emergency response in real time.
Mark
The 48-hour window is striking. Why does the risk jump so dramatically in the first two days?
Mimi
That's when the disease either stabilizes or accelerates. If your RDW is already high when you arrive, those first two days tell you whether your immune system is winning or losing. The ones with elevated RDW are already losing.
Mark
Could this have changed how doctors treated patients in 2020?
Mimi
Potentially, yes. If you could identify high-risk patients within hours of admission, you could escalate care earlier—more oxygen support, anticoagulation therapy, closer monitoring. Instead of waiting to see who got sicker, you'd know from the blood work.
El Pulso
- With nearly a million dead and clinicians still unable to reliably predict who would deteriorate, the pressure to find early warning tools was immense.
- Patients arriving with RDW above 14.5% faced nearly three times the mortality risk of those with normal levels — a gap that widened to more than six times within the first 48 hours of hospitalization.
- The signal held across every age group studied, from patients under 50 to those over 80, suggesting RDW was not merely a proxy for age or pre-existing frailty.
- When RDW rose during a hospital stay, mortality risk climbed further still — up to 40% for those who had already arrived with elevated levels, revealing the metric as a dynamic tracker of worsening, not just a snapshot of prior illness.
- Published in JAMA Network in September 2020, the findings pointed toward a practical intervention: a test already performed on admission could become a triage tool for targeting the patients most in need of aggressive care.
As the pandemic's death toll approached one million in late 2020, medicine was still searching for reliable signals amid the uncertainty of who would survive hospitalization. A Harvard research team found one such signal in an overlooked corner of routine blood work: the variation in size among a patient's red blood cells. Their study of 1,641 patients across Boston hospitals revealed that this ordinary measurement — red blood cell distribution width, or RDW — carried an extraordinary predictive weight, pointing toward mortality risk long before clinical deterioration became visible to the eye.
By late September 2020, the pandemic had claimed nearly a million lives, and clinicians were still struggling to identify which hospitalized patients would deteriorate rapidly. A Harvard Medical School team turned their attention to a number already hiding in routine blood work — red blood cell distribution width, or RDW — which measures how much red blood cells vary in size within the body.
Studying 1,641 patients admitted to four Boston-area hospitals between March and April 2020, the researchers tracked RDW daily alongside other markers. The patients had a mean age of 62. What emerged was a stark divide: those arriving with RDW above 14.5% faced a 31% mortality risk, compared to 11% for those at or below that threshold. The relative mortality risk was 2.73 times higher for elevated patients — and within 48 hours of admission, that figure climbed to 6.12 times, as high-RDW patients saw their risk jump by nearly five percent while low-RDW patients barely moved.
The pattern deepened when RDW rose during hospitalization. Patients who arrived with normal levels but saw them climb faced a 6 to 24% increase in mortality risk. Those who arrived already elevated and continued to rise faced increases of 22 to 40%. The metric was not simply reflecting who was already sick — it was tracking how sick they were becoming.
Published in JAMA Network on September 23, 2020, the study offered clinicians something actionable: a test already standard at admission could serve as an early flag for patients requiring closer monitoring or more aggressive intervention. In a moment when medicine was still learning the shape of the disease, the ordinary variation in red blood cells turned out to be one of its clearest early warnings.
By late September 2020, the pandemic had claimed nearly a million lives worldwide, with deaths clustering among the elderly and those already burdened by chronic illness. Doctors and researchers were still learning which patients would deteriorate rapidly and which might survive. A team at Harvard Medical School had been watching a particular number in the blood work of hospitalized COVID patients—one that seemed to predict who would die.
Red blood cell distribution width, or RDW, is a routine measurement from a standard blood test. It tells you how much the red blood cells in a person's body vary in size. The Harvard researchers studied 1,641 patients admitted to four Boston-area hospitals between early March and late April 2020, tracking their RDW alongside other markers like white blood cell counts and D-dimer levels. The patients had a mean age of 62 years. Every day, the scientists measured these values as the patients received standard care.
What they found was stark. Patients who arrived at the hospital with an RDW above 14.5 percent faced a 31 percent risk of death. Those with an RDW of 14.5 percent or lower faced an 11 percent risk. The difference held across age groups—it mattered whether you were under 50 or over 80. The relative risk of death for patients with elevated RDW was 2.73 times higher than for those with normal levels. But the picture darkened further in the first two days of hospitalization. Within 48 hours of admission, patients with normal RDW saw their mortality risk climb by less than one percent. Patients with high RDW saw theirs jump by nearly five percent. By that measure, a patient with elevated RDW at admission faced a mortality risk 6.12 times higher than a patient with normal RDW within the first two days in the hospital.
The researchers also tracked what happened when RDW rose during a patient's stay. For those who had started with normal levels, an elevation during hospitalization increased their mortality risk by between 6 and 24 percent. For those who had already arrived with high RDW, a further rise pushed their mortality risk up by 22 to 40 percent. The pattern suggested that RDW was not merely a marker of who was already sick—it was a signal of how sick they would become.
The study, published in JAMA Network on September 23, 2020, offered something clinicians could act on. A simple blood test, already routine in hospital admissions, could flag which COVID patients needed closer watching, more aggressive intervention, or different treatment strategies. It was a small tool in a moment when the pandemic was still teaching medicine what it needed to know. The finding suggested that the body's own variation in red blood cells—a measure so ordinary it barely registered in most medical conversations—could be one of the clearest early warnings of who would not survive.
Citas Notables
High RDW during hospital admission increases mortality risk by 6 to 24 percent for those with normal baseline RDW, and 22 to 40 percent for those already elevated at admission— Harvard Medical School researchers, JAMA Network study
Quieres la nota completa?
Lee el original en Firstpost ↗
Science & Space